Ekso Bionics (NASDAQ:EKSO) Announces Quarterly Earnings Results, Misses Estimates By $1.48 EPS

Ekso Bionics (NASDAQ:EKSO) released its quarterly earnings results on Monday. The company reported ($1.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($1.48), FiscalAI reports. The company had revenue of $3.14 million during the quarter, compared to analysts’ expectations of $5.03 million. Ekso Bionics had a negative return on equity of 90.71% and a negative net margin of 70.74%.

Ekso Bionics Price Performance

NASDAQ:EKSO traded down $0.54 during midday trading on Monday, hitting $10.64. 105,876 shares of the stock were exchanged, compared to its average volume of 286,111. The business has a 50-day moving average price of $8.30 and a two-hundred day moving average price of $5.78. The company has a current ratio of 1.66, a quick ratio of 1.09 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $27.88 million, a price-to-earnings ratio of -1.87 and a beta of 0.80. Ekso Bionics has a one year low of $2.73 and a one year high of $13.27.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on EKSO. Weiss Ratings restated a “sell (e+)” rating on shares of Ekso Bionics in a research note on Monday, December 22nd. HC Wainwright lowered shares of Ekso Bionics from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 31st. Finally, Wall Street Zen raised shares of Ekso Bionics to a “hold” rating in a report on Saturday, December 13th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $10.50.

Insider Buying and Selling at Ekso Bionics

In other news, major shareholder Daniel Asher bought 15,540 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The stock was acquired at an average price of $12.30 per share, with a total value of $191,142.00. Following the completion of the purchase, the insider directly owned 270,432 shares of the company’s stock, valued at $3,326,313.60. This represents a 6.10% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 6.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Ekso Bionics

Several hedge funds have recently made changes to their positions in EKSO. Virtu Financial LLC bought a new stake in Ekso Bionics during the third quarter worth approximately $57,000. Shay Capital LLC purchased a new stake in Ekso Bionics during the third quarter valued at about $67,000. Geode Capital Management LLC boosted its holdings in shares of Ekso Bionics by 68.9% in the fourth quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock worth $218,000 after buying an additional 10,281 shares during the period. Finally, Citadel Advisors LLC purchased a new position in shares of Ekso Bionics in the third quarter worth approximately $198,000. Institutional investors and hedge funds own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.